



# CONTENTS

2	م	A	I	A	I							
	I	A	IAL	I	LI	ق						
5	A	A	ق	ق	A	A	ALY	ق				
10	م	A	A	A	I	A	I					
17	م	I	I	I	A	IAL	A	I				
18	I	I	ق	ق	LI	A	ق	A	م	ق	I	
19	I	I	ق	ق	LI	A	ALA	ق				
21	I	I	ق	ق	LI	A	ق	A	A	ق	I	Y
22	I	I	ق	ق	LI	A	ق	A	A	ق	L	ق
23	ق	ق	ق	ق	LI	A	I	I	A	IAL	A	I





# FINANCIAL HIGHLIGHTS

	\$	RMB'000	( )	J . 30,	2016	'000	(Au )
Value		88,209			76,097		
Assets (1)		60,399			52,050		
Assets (2)		45,202			36,856		
Assets / m		68.5%			68. %		
Assets / m		51.2%			51. %		
Assets ( ) (3)		0.297			0.292		
Assets							
Assets		17,686			1,302		
Assets		735			—		
Assets		20,821			10,992		
Assets		8,393			—		

(1) ... 2.0 million ...

(2) ... 2 million ...

(3) ... 0.103 ...



# MANAGEMENT DISCUSSION AND ANALYSIS

## FINANCIAL REVIEW

### Revenue

Revenue

Revenue decreased 15.9% from 76.1 million RMB for the six months ended June 30, 2016 to 64.2 million RMB for the six months ended June 30, 2017. The decrease was primarily due to the decrease in the number of patients treated at the hospital.

	\$	June 30,
	2017	2016
	RMB'000	'000
	( )	(Au )
Revenue from operations	12,980	9,286
Revenue from other operations	4,258	3,725
Revenue from investment	70,207	62,300
Revenue from other sources	764	656
	<u>88,209</u>	<u>76,097</u>

Revenue from operations

Revenue from operations decreased 32.5% from 13.0 million RMB for the six months ended June 30, 2016 to 8.8 million RMB for the six months ended June 30, 2017. The decrease was primarily due to the decrease in the number of patients treated at the hospital. Revenue from other operations decreased 12.9% from 3.7 million RMB for the six months ended June 30, 2016 to 4.3 million RMB for the six months ended June 30, 2017. Revenue from investment decreased 12.1% from 62.3 million RMB for the six months ended June 30, 2016 to 70.2 million RMB for the six months ended June 30, 2017. Revenue from other sources decreased 16.4% from 0.7 million RMB for the six months ended June 30, 2016 to 0.8 million RMB for the six months ended June 30, 2017.





## MANAGEMENT DISCUSSION AND ANALYSIS

### Financial Results

Our total revenue increased by 3.0% to RMB 1.56 billion in 2017, compared with RMB 1.51 billion in 2016. The increase was primarily driven by the growth in the number of patients and the average length of stay, partially offset by a decrease in the average daily rate.

### Operating Results

As a result of the above, our operating profit increased by 7.1% to RMB 135.8 million in 2017, compared with RMB 127.0 million in 2016.

Our operating margin increased by 9.8 percentage points to 8.7% in 2017, compared with 7.8% in 2016. The increase was primarily due to the improvement in the operating margin of our core business, which was driven by the increase in the number of patients and the average length of stay, partially offset by a decrease in the average daily rate.

### Assets and Liabilities

Our total assets increased by 2.6 million to RMB 1.56 billion in 2017, compared with RMB 1.54 billion in 2016. The increase was primarily driven by the growth in the number of patients and the average length of stay, partially offset by a decrease in the average daily rate. Our total liabilities increased by 0.5 million to RMB 407.0 million in 2017, compared with RMB 406.5 million in 2016. The increase was primarily driven by the growth in the number of patients and the average length of stay, partially offset by a decrease in the average daily rate.

## MANAGEMENT DISCUSSION AND ANALYSIS

Our consolidated financial statements for 2017 were prepared in accordance with the IFRS as issued by the IASB, as applicable to the reporting entity, and are presented in Canadian dollars. The consolidated financial statements for 2017 were prepared in accordance with the IFRS as issued by the IASB, as applicable to the reporting entity, and are presented in Canadian dollars. The consolidated financial statements for 2017 were prepared in accordance with the IFRS as issued by the IASB, as applicable to the reporting entity, and are presented in Canadian dollars.

### A. Financial Performance

Our consolidated financial statements for 2017 were prepared in accordance with the IFRS as issued by the IASB, as applicable to the reporting entity, and are presented in Canadian dollars. The consolidated financial statements for 2017 were prepared in accordance with the IFRS as issued by the IASB, as applicable to the reporting entity, and are presented in Canadian dollars.

## CORPORATE GOVERNANCE AND OTHER INFORMATION

### USE OF PROCEEDS FROM THE LISTING

As of the end of the reporting period, the net proceeds from the listing of the Company's shares on the Main Board of the Stock Exchange of Hong Kong Limited, after deducting the expenses incurred in connection with the listing, amounted to approximately \$65.6 million. As at 30, 2017, the net proceeds from the listing of the Company's shares on the Main Board of the Stock Exchange of Hong Kong Limited, after deducting the expenses incurred in connection with the listing, amounted to approximately \$65.6 million.

### EXPOSURE TO FOREIGN EXCHANGE RISK

The Company's operations are primarily conducted in the United States and the United Kingdom. The Company's revenue is primarily generated from the United States and the United Kingdom. The Company's expenses are primarily incurred in the United States and the United Kingdom. The Company's assets and liabilities are primarily denominated in the United States dollar and the United Kingdom pound sterling.

### PLEDGE OF ASSETS

As at the end of the reporting period, the Company does not have any assets pledged.

### MATERIAL INTERESTS

The Company does not have any material interests.

### MATERIAL ACQUISITIONS AND DISPOSALS

The Company has not made any material acquisitions or disposals during the reporting period.

### EVENTS AFTER THE REPORTING PERIOD

The Company has not had any events after the reporting period.



## CORPORATE GOVERNANCE AND OTHER INFORMATION

### IN REVENUE AND SHORT POSITIONS OF SUBSIDIARIAL SHAREHOLDERS

As at 30, 2017, following the completion of the acquisition of the subsidiary, the Company has the following information on the subsidiaries and their financial information:









## CORPORATE GOVERNANCE AND OTHER INFORMATION

### A DI COMMITTEE

u u -g- s -c- s -c- s f -c- s m -s f -u f- s m- s  
u

# REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION

THE BOARD OF DIRECTORS OF HOSPITAL CORPORATION OF CHINA LIMITED

(Incorporated in the People's Republic of China)

## INTERIM FINANCIAL INFORMATION

As at 30 June 2017, the interim financial information of the Company is set out in the interim financial statements of the Company for the period ended 30 June 2017, which are included in the interim financial report of the Company for the period ended 30 June 2017. The interim financial information is unaudited and does not constitute an audit opinion.

# INTERIM CONDENSED CONSOLIDATED STATE

		\$	J u n e 30,
		2017	2016
		RMB'000	'000
		( )	(Au )
7		88,209	76,097
		(46,231)	(25,399)
		41,978	50,708
		—	(1)
		(28,252)	(16,038)
		(232)	522
		1,623	569
		15,117	35,800
10		662	9
10		(8,393)	—
		7,386	35,899
11		(9,819)	(11,287)
		(2,433)	2,562
		—	—
		(2,433)	2,562
		(12,291)	16,62
		9,858	8,100
		(2,433)	2,562
12		(0.103)	0.167

2017年6月30日止期间财务报表

## INTERIM CONDENSED CONSOLIDATED BALANCE SHEET

		June 30, 2017 RMB'000 ( )	December 31, 2016 '000 (Au )
<b>ASSETS</b>			
Non-current assets			
Property, plant and equipment	13	21,438	22,630
Intangible assets	13	1,080,325	1,082,071
Financial assets	21	244	276
Other non-current assets	15	548	—
		<u>1,102,555</u>	<u>1,107,977</u>
Current assets			
Accounts receivable	5.3 ( )	80,933	—
Inventory		1,485	1,877
Other current assets	1	5,172	575
Other non-current assets	15	708	8,570
Amortizable intangible assets	16	41,778	38,276
Other current assets		456,556	129,332
Other non-current assets		30,000	—
		<u>616,632</u>	<u>182,600</u>
		<u>1,719,187</u>	<u>1,287,577</u>
<b>EQUITY</b>			
Equity attributable to owners of the parent			
Capital	17	123	65
Reserves	17	404,021	—
Other equity	17	(3)	(2)
Other non-current assets	18	1,060,802	1,058,166
		<u>48,306</u>	<u>60,597</u>
		<u>1,513,249</u>	<u>1,119,076</u>
Non-current liabilities		51,725	1,867
		<u>1,564,974</u>	<u>1,160,943</u>

## INTERIM CONDENSED CONSOLIDATED BALANCE SHEET

		June 30, 2017 RMB'000 ( )	December 31, 2016 '000 (Au )
<b>LIABILITIES</b>			
<b>Non-current liabilities</b>			
Financial guarantees	21	37,375	36,655
Accounts payable	20	2,866	19,122
		<u>40,241</u>	<u>55,907</u>
<b>Current liabilities</b>			
Accounts payable	16	4,697	3,855
Accounts payable	19	3,622	3,631
Accounts payable	20	100,191	97,838
Accounts payable			

## INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	A. Balance at the beginning of the period		B. Changes during the period		C. Balance at the end of the period		A. Balance at the beginning of the period	
	\$ RMB' 000	\$ RMB' 000	\$ RMB' 000	RMB' 000 (Note 18)	RMB' 000	\$ RMB' 000	RMB' 000	RMB' 000
(Continued)								
Balance at January 1, 2017	65	(2)	—	1,058,416	60,597	1,119,076	41,867	1,160,943
Changes during the period:								
(Loss)/Profit	—	—	—	—	(12,291)	(12,291)	9,858	(2,433)
Remeasurement of defined pension plans	17(1)	(65)	2	—	63	—	—	—
Dividends	17(1)	—	—	—	—	—	—	—
Cash contributions	17(1)	89	(3)	(86)	—	—	—	—
Liabilities								
Employee share options	17(1)	34	—	434,827	—	—	—	434,861
Share-based payments	17(1)	—	—	(30,720)	—	—	—	(30,720)
Share repurchases		—	—	—	2,323	—	—	2,323
Balance at December 30, 2017	<u>123</u>	<u>(3)</u>	<u>404,021</u>	<u>1,060,802</u>	<u>48,306</u>	<u>1,513,249</u>	<u>51,725</u>	<u>1,564,974</u>
(Continued)								
Balance at January 1, 2016	—	—	—	1,015,707	5,200	1,090,077	38,922	1,128,539
Changes during the period:								
Profit	—	—	—	—	16,622	16,622	8,100	23,622
Liabilities	17	2	—	31,190	—	—	—	31,190
Share repurchases		—	—	—	—	—	—	—

## INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

	\$	June 30,
	2017	2016
	RMB'000	'000
	( )	(Au )
<b>Cash flows from operating activities</b>		
Net income	42,727	12,276
Adjustments to reconcile net income to cash flows from operating activities	(7,818)	(18,172)
Changes in non-current assets and liabilities	662	9
<b>Net cash flows from operating activities</b>	<b>35,571</b>	<b>12,113</b>
<b>Cash flows from investing activities</b>		
Acquisition of subsidiaries, net of cash acquired	(775)	(10,880)
Acquisition of subsidiaries, net of cash acquired	5.3( ) (93,100)	—
Acquisition of subsidiaries, net of cash acquired	(30,000)	—
Acquisition of subsidiaries, net of cash acquired	5.3( ) 12,2( )	E EM0) . 403.9156 ( ) (G)





# NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

## 3 ACCOUNTING POLICIES

### (i) Investment in subsidiaries

The Group's investment in subsidiaries is measured at cost less impairment. Cost includes the fair value of any consideration transferred, plus any directly attributable incremental costs, less any identifiable intangible assets acquired. The carrying amount of investments in subsidiaries is reviewed for impairment at each reporting date, and impairment losses are recognized where the carrying amount of the investment exceeds the recoverable amount. Recoverable amount is the maximum of fair value less costs of disposal and value in use.

Example:  
 Investment in subsidiaries

Accounting Policy	Description	Unit
19	Investment in subsidiaries	USD million
15	Investment in subsidiaries	USD million
16	Investment in subsidiaries	USD million
Amendment 2	Investment in subsidiaries	USD million
Amendment 10	Investment in subsidiaries	USD million

### (ii) Investment in associates

The Group's investment in associates is measured at cost less impairment. Cost includes the fair value of any consideration transferred, plus any directly attributable incremental costs, less any identifiable intangible assets acquired. The carrying amount of investments in associates is reviewed for impairment at each reporting date, and impairment losses are recognized where the carrying amount of the investment exceeds the recoverable amount. Recoverable amount is the maximum of fair value less costs of disposal and value in use.

Example:  
 Investment in associates

- Investment in associates
- Investment in associates

# NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

## 3 ACCOUNTING POLICIES

### (i) Intangible Assets

#### (a) Intangible Assets

Intangible assets are identifiable non-monetary assets without physical substance. Intangible assets are recognized if they are identifiable and the company can demonstrate control over the asset. Intangible assets are measured at cost less accumulated amortization and impairment losses. Amortization is calculated on a straight-line basis over the estimated useful life of the asset. The useful life of an intangible asset is determined based on the expected period over which the asset will generate cash flows for the company. Intangible assets with indefinite useful lives are not amortized.

The company's intangible assets consist of software licenses, patents, and trademarks. Software licenses are amortized over their useful life, which is generally 3 to 5 years. Patents and trademarks are amortized over their legal life, which is generally 10 to 20 years. Intangible assets are tested for impairment at the end of each reporting period, or more frequently if there are indicators of impairment. An impairment loss is recognized if the carrying amount of an intangible asset exceeds its recoverable amount.

The company's intangible assets are measured at cost less accumulated amortization and impairment losses. Amortization is calculated on a straight-line basis over the estimated useful life of the asset. The useful life of an intangible asset is determined based on the expected period over which the asset will generate cash flows for the company. Intangible assets with indefinite useful lives are not amortized.

#### (b) Intangible Assets

Intangible assets are identifiable non-monetary assets without physical substance. Intangible assets are recognized if they are identifiable and the company can demonstrate control over the asset. Intangible assets are measured at cost less accumulated amortization and impairment losses. Amortization is calculated on a straight-line basis over the estimated useful life of the asset. The useful life of an intangible asset is determined based on the expected period over which the asset will generate cash flows for the company. Intangible assets with indefinite useful lives are not amortized.

The company's intangible assets consist of software licenses, patents, and trademarks. Software licenses are amortized over their useful life, which is generally 3 to 5 years. Patents and trademarks are amortized over their legal life, which is generally 10 to 20 years. Intangible assets are tested for impairment at the end of each reporting period, or more frequently if there are indicators of impairment. An impairment loss is recognized if the carrying amount of an intangible asset exceeds its recoverable amount.

The company's intangible assets are measured at cost less accumulated amortization and impairment losses. Amortization is calculated on a straight-line basis over the estimated useful life of the asset. The useful life of an intangible asset is determined based on the expected period over which the asset will generate cash flows for the company. Intangible assets with indefinite useful lives are not amortized.

The company's intangible assets consist of software licenses, patents, and trademarks. Software licenses are amortized over their useful life, which is generally 3 to 5 years. Patents and trademarks are amortized over their legal life, which is generally 10 to 20 years. Intangible assets are tested for impairment at the end of each reporting period, or more frequently if there are indicators of impairment. An impairment loss is recognized if the carrying amount of an intangible asset exceeds its recoverable amount.

The company's intangible assets are measured at cost less accumulated amortization and impairment losses. Amortization is calculated on a straight-line basis over the estimated useful life of the asset. The useful life of an intangible asset is determined based on the expected period over which the asset will generate cash flows for the company. Intangible assets with indefinite useful lives are not amortized.

The company's intangible assets consist of software licenses, patents, and trademarks. Software licenses are amortized over their useful life, which is generally 3 to 5 years. Patents and trademarks are amortized over their legal life, which is generally 10 to 20 years. Intangible assets are tested for impairment at the end of each reporting period, or more frequently if there are indicators of impairment. An impairment loss is recognized if the carrying amount of an intangible asset exceeds its recoverable amount.

The company's intangible assets are measured at cost less accumulated amortization and impairment losses. Amortization is calculated on a straight-line basis over the estimated useful life of the asset. The useful life of an intangible asset is determined based on the expected period over which the asset will generate cash flows for the company. Intangible assets with indefinite useful lives are not amortized.

# NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

## 3 ACCOUNTING POLICIES

### (i) Investment in subsidiaries

#### (i) Investment in subsidiaries

Investment in subsidiaries is measured at cost less impairment. Impairment testing is performed annually or more frequently if indicators of impairment exist. For investments in subsidiaries, impairment testing is performed by comparing the carrying amount of the investment to its recoverable amount. Recoverable amount is the maximum of fair value less costs of disposal and value in use. Where the carrying amount exceeds the recoverable amount, the investment is impaired and the carrying amount is reduced to its recoverable amount. Impairment losses are recognized in the consolidated income statement.

Investment in subsidiaries is measured at cost less impairment. Impairment testing is performed annually or more frequently if indicators of impairment exist. For investments in subsidiaries, impairment testing is performed by comparing the carrying amount of the investment to its recoverable amount. Recoverable amount is the maximum of fair value less costs of disposal and value in use. Where the carrying amount exceeds the recoverable amount, the investment is impaired and the carrying amount is reduced to its recoverable amount. Impairment losses are recognized in the consolidated income statement.

Investment in subsidiaries is measured at cost less impairment. Impairment testing is performed annually or more frequently if indicators of impairment exist. For investments in subsidiaries, impairment testing is performed by comparing the carrying amount of the investment to its recoverable amount. Recoverable amount is the maximum of fair value less costs of disposal and value in use. Where the carrying amount exceeds the recoverable amount, the investment is impaired and the carrying amount is reduced to its recoverable amount. Impairment losses are recognized in the consolidated income statement.

#### (v) Amortization of intangible assets

Intangible assets with finite useful lives are amortized over their estimated useful lives, commencing when the asset is available for use. Amortization expense is recognized in the consolidated income statement. Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually, or more frequently if indicators of impairment exist.

# NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

## 4 EŞİTİM VE İZLENİM

İzlenim, şirketin faaliyetleri, finansal durumu, riskleri, fırsatları ve gelecekteki performansını değerlendirmek için yapılan çalışmaları kapsar. İzlenim, şirketin faaliyetleri, finansal durumu, riskleri, fırsatları ve gelecekteki performansını değerlendirmek için yapılan çalışmaları kapsar. İzlenim, şirketin faaliyetleri, finansal durumu, riskleri, fırsatları ve gelecekteki performansını değerlendirmek için yapılan çalışmaları kapsar.

## 5 FINANCIAL RISK MANAGEMENT AND FINANCIAL INSTRUMENTS

### 5.1 Finansal Risk Yönetimi

Şirketin finansal risk yönetimi, şirketin faaliyetleri, finansal durumu, riskleri, fırsatları ve gelecekteki performansını değerlendirmek için yapılan çalışmaları kapsar. Şirketin finansal risk yönetimi, şirketin faaliyetleri, finansal durumu, riskleri, fırsatları ve gelecekteki performansını değerlendirmek için yapılan çalışmaları kapsar. Şirketin finansal risk yönetimi, şirketin faaliyetleri, finansal durumu, riskleri, fırsatları ve gelecekteki performansını değerlendirmek için yapılan çalışmaları kapsar.

### 5.2 Likidite Riski

Şirketin likidite riski, şirketin faaliyetleri, finansal durumu, riskleri, fırsatları ve gelecekteki performansını değerlendirmek için yapılan çalışmaları kapsar. Şirketin likidite riski, şirketin faaliyetleri, finansal durumu, riskleri, fırsatları ve gelecekteki performansını değerlendirmek için yapılan çalışmaları kapsar. Şirketin likidite riski, şirketin faaliyetleri, finansal durumu, riskleri, fırsatları ve gelecekteki performansını değerlendirmek için yapılan çalışmaları kapsar.



# NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

## 5 FINANCIAL RISK MANAGEMENT AND FINANCIAL INSTRUMENTS

### 5.3 Financial Instruments

(a) Financial Instruments

The following table summarizes the financial instruments as at 31 December 2016 and 30 June 2017.

	RMB'000	USD'000
Financial assets	93,100	—
Financial liabilities	(12,200)	—
Financial instruments	33	—
Financial assets	80,933	—
Financial liabilities	—	—
Financial instruments	33	—
Financial assets	—	—
Financial liabilities	—	—
Financial instruments	—	—

The following table summarizes the financial instruments as at 31 December 2016 and 30 June 2017. The financial instruments are measured at fair value. The fair value of financial instruments is determined based on the closing price of the instruments in the active market. The fair value of financial instruments is determined based on the closing price of the instruments in the active market.

## NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

### 5 FINANCIAL RISK MANAGEMENT AND FINANCIAL INSTRUMENTS

#### 5.3 Financial Instruments





## NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

### 6 SEGMENT INFORMATION

(i) Hospital

Revenue from operations of the Hospital segment is derived from the provision of medical services, including hospitalization, outpatient services, medical examinations, and medical treatments.

(ii) Others

Revenue from operations of the Others segment is derived from the provision of medical services, including hospitalization, outpatient services, medical examinations, and medical treatments.

## NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

### 6 SEGMENT INFORMATION - CONTINUED

Segment information is reported in US dollars unless otherwise indicated.

US \$ million  
 US \$ million  
 US \$ million  
 US \$ million  
 US \$ million

(A) (continued)

As at June 30, 2016

	US \$ million	US \$ million	US \$ million	US \$ million
Investment	13,011	63,086	—	76,097
Intangible Assets	(209)	9,995	—	9,786
Accumulated amortization	(289)	(880)	(998)	(1,767)
Accumulated impairment losses	(575)	(1,153)	—	(1,728)
Goodwill	6	3	—	9
Impairment losses	—	—	(10,91)	(10,91)
Net identifiable intangible assets	(1,067)	8,005	(11,089)	35,889

(A) (continued)

As at June 30, 2016

Investment	26,07	272,278	23,85	322,197
Goodwill	7,98	950,916	—	958,896
Intangible assets	3,022	1,223,19	23,85	1,281,061
Impairment losses	16,965	8,25	30,116	95,506

(A) (continued)


As at June 30, 2016

Investment	(1,37)	(2,033)	(998)	( ,068)
Goodwill	369	1,95	—	2,323

## NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

### 7 REVENUE

\$ 1,234,567,890 June 30,



NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

8 OTHER (LOSSES)/GAINS—NET

	June 30,
	2016
	'000
	(Audited)
Change in fair value of derivatives	\$23
Other	—
	(1)
	<u>\$22</u>

9 OTHER INCOME

	June 30,
	2016
	'000
	(Audited)
Interest income	\$69
Other	—
	<u>\$69</u>

# NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

## 11 INCOME AND EXPENSE

The following table sets out the components of income and expense for the periods ended 30 June 2017 and 30 June 2016. The amounts are in RMB'000 unless otherwise stated.

	30 June 2017	30 June 2016
	RMB'000	RMB'000
	( )	( )
Operating income	8,877	8,316
Operating expenses (including depreciation and amortisation)	942	2,971
<b>Operating profit</b>	<b>9,819</b>	<b>11,287</b>

### (a) Operating income

Operating income consists of the following components:

### (i) Hospital services

Operating income from hospital services was RMB16.5% (30 June 2016: 16.5%) for the period ended 30 June 2017. This increase was primarily due to an increase in the number of hospital services provided during the period ended 30 June 2017 compared to the period ended 30 June 2016.

### (ii) PRC C... (C...)

Operating income from PRC C... was RMB2.5% (30 June 2016: 2.5%) for the period ended 30 June 2017. This increase was primarily due to an increase in the number of PRC C... provided during the period ended 30 June 2017 compared to the period ended 30 June 2016.

( ) 5.10, 1.20 Td (f1.69 0 Td ( 1.69 0 Td ( (s)Tj ( )Tji( )Tj 3.824( )Tj(H)Tj5.4348 0 Td E Td ( (s)Tj ( )Tj0 Td ( 1.69 p( )Tj 1.69

9%) ( ) 7) s 17 67 0 ( ) ( 88 ( ) ( ) ( ) 08) ( ) 1.69 0 (f1.69 0

# NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

## 12 (LOSSES)/EARNINGS PER SHARE

( ) Basic (Losses)/Earnings Per Share

	\$ million	
	2017	2016
	(A\$ million)	(A\$ million)
Losses attributable to ordinary shareholders of the Company	(12,291)	16,62
Weighted average number of ordinary shares outstanding (in thousands)	118,860	98,30
Basic (Losses)/Earnings Per Share (A\$)	<u>(0.103)</u>	<u>0.167</u>

Losses attributable to ordinary shareholders of the Company for the period ended 31 March 2017 were \$12,291 million (2016: \$16,62 million).

Weighted average number of ordinary shares outstanding for the period ended 31 March 2017 was 118,860 thousand (2016: 98,30 thousand).

Basic (Losses)/Earnings Per Share for the period ended 31 March 2017 was (0.103) A\$ (2016: 0.167 A\$).

On 3 April 2017, the Company issued 9,986 thousand shares at a price of \$0.001 per share. The total proceeds from the issue were \$9,986 thousand. The shares were issued to the public through a public offering. The issue was oversubscribed and the Company received a total of \$1.00 per share. The total number of shares issued was 9,986 thousand.

On 16 April 2017, the Company issued 99,850,010 shares at a price of \$0.001 per share. The total proceeds from the issue were \$99,850,010 thousand. The shares were issued to the public through a public offering. The issue was oversubscribed and the Company received a total of \$1.00 per share. The total number of shares issued was 99,850,010 thousand.

On 16 April 2017, the Company issued 3,333,600 shares at a price of \$0.001 per share. The total proceeds from the issue were \$3,333,600 thousand. The shares were issued to the public through a public offering. The issue was oversubscribed and the Company received a total of \$1.00 per share. The total number of shares issued was 3,333,600 thousand.

On 13 April 2017, the Company issued 5,000,000 shares at a price of \$0.001 per share. The total proceeds from the issue were \$5,000,000 thousand. The shares were issued to the public through a public offering. The issue was oversubscribed and the Company received a total of \$1.00 per share. The total number of shares issued was 5,000,000 thousand.

( ) Diluted (Losses)/Earnings Per Share

Nil

## NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

### 13 PROPERTIES, PLANT AND EQUIPMENT AND INTANGIBLE ASSETS

	Period ended June 30, 2017 RMB'000	Period ended June 30, 2016 RMB'000	Period ended June 30, 2016 RMB'000
Net book value			
At the beginning of the period	22,630	123,207	95,886
Acquisitions	516	—	—
Disposals	—	—	—
Depreciation and amortization	(1,708)	(1,766)	—
At the end of the period	<u>21,438</u>	<u>121,441</u>	<u>95,886</u>
Net book value			
At the beginning of the period	23,625	126,887	95,886
Acquisitions	2,323	—	—
Disposals	—	—	—
Depreciation and amortization	(1,767)	(1,728)	—
At the end of the period	<u>24,181</u>	<u>125,159</u>	<u>95,886</u>

### 14 TRADE RECEIVABLES

	At the end of June 30, 2017 RMB'000 (Audited)	At the end of June 30, 2016 RMB'000 (Audited)
Trade receivables	5,681	5,213
Allowance for doubtful debts	(509)	(638)
Trade receivables, net	<u>5,172</u>	<u>4,575</u>

## NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

### 14 TRADE RECEIVABLES

As at 30, 2017 compared 31, 2016,  
 in million RMB

1-90 days  
 91-180 days  
 181 days  
 over 1

As at June 30, 2017 RMB'000 ( )	As at June 31, 2016 '000 (Au )
2,751	,91
2,542	—
388	—
—	699
<b>5,681</b>	<b>,213</b>

### 15 OTHER RECEIVABLES, DEPOSITS AND PREPAYMENTS

in million RMB  
 in million RMB

As at June 30, 2017 RMB'000 ( )	As at June 31, 2016 '000 (Au )
347	331
81	



## NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

### 16 BALANCE SHEET RELATED PARTIES

As at 30, 2017 and 31, 2016, the following table shows the balance sheet related parties.

	As at 30, 2017 RMB'000	As at 31, 2016 '000
Accounts receivable	41,678	38,175
Accounts payable	57	6
Prepaid expenses	27	30
Other receivables	8	13
Other payables	8	—
Other assets	—	12
<b>Total</b>	<b>41,778</b>	<b>38,276</b>

As at 30, 2017 and 31, 2016, the following table shows the balance sheet related parties.

	As at 30, 2017 RMB'000	As at 31, 2016 '000
Accounts receivable	41,678	38,175
Accounts payable	—	—
Prepaid expenses	—	—
Other receivables	—	—
Other payables	—	—
Other assets	—	—
<b>Total</b>	<b>41,678</b>	<b>38,175</b>

## NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

### 16 BALANCES OF RELATED PARTIES

As at 30, 2017, the following balances were in million (2016: million).

	As at June 30, 2017 RMB'000 (Audited)	As at December 31, 2016 '000 (Audited)
Accounts receivable	4,136	2,937
Due from related parties	561	918
	<u>4,697</u>	<u>3,855</u>

Amounts due to related parties are classified as non-current liabilities. The carrying amounts of these liabilities are disclosed in the consolidated balance sheet as of June 30, 2017 and December 31, 2016, respectively.

## NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

### 17 SHARE CAPITAL, RESERVE SHARES AND SHARE PREMIUM

## NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

17 ~~SHARE CAPITAL, RESERVE SHARES AND SHARE PREMIUM~~ ~~—~~ ~~CU~~

( ) ~~—~~ ~~S~~



# NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

## 19 TRADE PAYABLES

	As at December 31, 2017 RMB'000 ( )	As at December 31, 2016 '000 (Au )
Accounts payable	3,595	,60
Other payables	—	—
Prepaid expenses	—	—
Due from related parties	27	27
	<u>3,622</u>	<u>,631</u>

The carrying amount of trade payables is denominated in RMB. The carrying amount of other payables is denominated in RMB.

## 20 ACCRUALS, OTHER PAYABLES AND PROVISIONS

	As at December 31, 2017 RMB'000 ( )	As at December 31, 2016 '000 (Au )
Accrued interest	6,219	11,217
Accrued salaries and bonuses	34,805	19,2
Accrued expenses	30,591	30,23
Accrued interest on bank deposits	21,984	6,839
Accrued interest on bank borrowings	158	167
Accrued interest on other financial assets	2,648	2,67
Accrued interest on other financial liabilities	2,549	5,357
Accrued interest on other financial liabilities	4,103	1,377
	<u>103,057</u>	<u>77,280</u>
Provisions	2,866	19,2
	<u>100,191</u>	<u>57,838</u>

The carrying amount of accruals and provisions is denominated in RMB. The carrying amount of other payables is denominated in RMB.

## NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

21 DE

## NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

### 21 DEFERRED INCOME TAX

Deferred income tax

	December 31, 2017	December 31, 2016	December 31, 2015
	RMB' 000	RMB' 000	RMB' 000
(Note 12)			
December 31, 2017	(30,758)	(5,707)	(36,465)
/(December 31) - deferred income tax	432	(1,342)	(910)
<b>Balance at December 31, 2017</b>	<b>(30,326)</b>	<b>(7,049)</b>	<b>(37,375)</b>
(A note 12)			
December 31, 2016	(31,622)	(8,771)	(37,069)
/(December 31) - deferred income tax	32	(3,966)	(3,111)
<b>Balance at December 31, 2016</b>	<b>(31,190)</b>	<b>(8,993)</b>	<b>(10,183)</b>

### 22 DIVIDENDS

There were no dividends declared or paid by the Company during the reporting period (December 31, 2017 (December 31, 2016)).

### 23 COMMITMENTS

(Note 12)

The Company has entered into various contracts with suppliers and customers, which are subject to the terms and conditions of the contracts.

	December 31, 2017	December 31, 2016
	RMB' 000	'000
(Note 12)		(Audited)
Contractual obligations	4,357	2,376
Contractual obligations	9,493	7,833
Contractual obligations	—	1,038
<b>Contractual obligations</b>	<b>13,850</b>	<b>11,247</b>





# NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

## 24 SIGNIFICANT RELATED PARTY TRANSACTIONS

( ) Significant related party transactions

	\$ million, unless otherwise stated, as at June 30,	
	2017	2016
	RMB'000	'000
	( )	(Au )
Management services	70,207	62,30

( ) Board of directors

Management services provided to the Company during the period ended June 30, 2017 were \$16 million.

( ) Key management personnel

Management services provided to the Company during the period ended June 30, 2017 were \$16 million. Management services provided to the Company during the period ended June 30, 2016 were \$16 million.

	\$ million, unless otherwise stated, as at June 30,	
	2017	2016
	RMB'000	'000
	( )	(Au )
Management services		

## NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

### 25 應 收 賬 款 及 其 他 應 收 賬 款

#### (i) 附 屬 公 司

於 2017 年 10 月 31 日，應收賬款及應收票據總額為 120,000,000 美元（「美元」），其中 120,000,000 美元為應收賬款。於 2017 年 3 月 31 日，應收賬款及應收票據總額為 120,000,000 美元。於 2017 年 10 月 31 日，應收賬款及應收票據的賬齡分析如下：

#### (ii) 附 屬 公 司

於 2017 年 9 月 30 日，應收賬款及應收票據總額為 80% 的附屬公司。於 2017 年 10 月 31 日，應收賬款及應收票據總額為 80% 的附屬公司。於 2017 年 10 月 31 日，應收賬款及應收票據的賬齡分析如下：